ARPA-H Taps Exthymic for Up to $25M Cell Therapy Device Contract
The San Diego-based company was awarded the contract by the Advanced Research Projects Agency for Health, an agency inside the U.S. Department of Health and Human Services.
Exthymic Corporation, a San Diego-based company, has been awarded up to $25M in funding, according to an announcement dated October 5, 2026.
The money comes not from a venture round but from the Advanced Research Projects Agency for Health, an agency within the U.S. Department of Health and Human Services. ARPA-H has awarded Exthymic a contract to develop a cell therapy device.
The stated aim of that work is to address key issues underlying patient access and affordability — two persistent pressure points in cell therapy, where manufacturing complexity and cost have historically limited how widely treatments reach patients.
The announcement did not name any private investors, venture firms, or other participants in the funding, and no equity round was disclosed. It also did not specify a payment schedule for the $25M figure, which is described as an amount of "up to" that ceiling rather than a fixed sum. Additional terms of the contract were not released.
Exthymic did not disclose how it intends to allocate the funds beyond the device development work described in the award, and the announcement contained no details on the company's headcount, prior financing, valuation, or revenue.
The award places Exthymic among the recipients of ARPA-H funding, a channel that has become a notable alternative to traditional venture capital for companies working on health technologies that carry long development timelines or uncertain commercial paths. Government contracts of this type can fund research that private investors may be reluctant to underwrite on their own, though they typically come with milestones and deliverables attached.
For Exthymic, the contract gives the company a federally backed mandate to pursue a device intended to widen access to cell therapy and lower its cost — a goal that, if met, would touch a broad slice of the patient population that currently faces barriers to such treatments.
The announcement offered no timeline for development, no indication of when the device might reach clinical or commercial stages, and no information about partnerships or manufacturing arrangements. Whether the full $25M is ultimately drawn down will depend on terms that were not made public.
Exthymic is based in San Diego, California.